» Articles » PMID: 36771237

DSM 17938-Containing Infant Formulas and the Associations with Gastrointestinal Tolerance: A Cross-Sectional Observational Study

Overview
Journal Nutrients
Date 2023 Feb 11
PMID 36771237
Authors
Affiliations
Soon will be listed here.
Abstract

(.; previously ) has been shown to influence gastrointestinal (GI) tolerance. This study was a secondary analysis of GI tolerance data from a multi-country, cross-sectional, observational study in healthy infants using the validated Infant Gastrointestinal Symptom Questionnaire (IGSQ) and a gut comfort questionnaire. Breastfed infants (BFI; = 760) were compared to formula-fed infants receiving either -containing formula (FFI + LR; = 470) or standard formula without any probiotic or prebiotic (FFI-Std; = 501). The IGSQ composite scores (adjusted mean ± SE) in FFI + LR (22.17 ± 0.39) was significantly lower than in FFI-Std (23.41 ± 0.37) and similar to BFI (22.34 ± 0.30;), indicating better GI tolerance in FFI + LR than in FFI-Std. Compared with FFI-Std, FFI + LR had lower reports of difficulty in passing stools (11% vs. 22%; adjusted-odds ratio (OR) (95%CI) = 0.46 (0.31-0.68)), fewer hard stools (mean difference = -0.12 (-0.21, -0.02)) and less physician-confirmed colic (OR = 0.61 (0.45-0.82)), and similar to BFI. Parent-reported crying time (mean difference = -0.15 (-0.28, -0.01)), frequency of spitting-up/vomiting (mean difference = -0.18 (-0.34, -0.03)), volume of spit-up (mean difference = -0.20 (-0.32, -0.08)) and fussiness due to spitting-up/vomiting (mean difference = -0.17 (-0.29, -0.05)) were lower in FFI + LR versus FFI-Std and similar to BFI. In this study, -containing formula was associated with improved digestive tolerance and behavioral patterns.

Citing Articles

Comparative efficacy of probiotic mixture Bifidobacterium longum KABP042 plus Pediococcus pentosaceus KABP041 vs. Limosilactobacillus reuteri DSM17938 in the management of infant colic: a randomized clinical trial.

Moreno-Villares J, Andrade-Platas D, Soria-Lopez M, Colome-Rivero G, Catalan Lamban A, Martinez-Figueroa M Eur J Pediatr. 2024; 183(12):5371-5381.

PMID: 39390276 PMC: 11527960. DOI: 10.1007/s00431-024-05806-x.


in digestive system diseases: focus on clinical trials and mechanisms.

Peng Y, Ma Y, Luo Z, Jiang Y, Xu Z, Yu R Front Cell Infect Microbiol. 2023; 13:1254198.

PMID: 37662007 PMC: 10471993. DOI: 10.3389/fcimb.2023.1254198.

References
1.
QUINLAN P, Lockton S, Irwin J, Lucas A . The relationship between stool hardness and stool composition in breast- and formula-fed infants. J Pediatr Gastroenterol Nutr. 1995; 20(1):81-90. DOI: 10.1097/00005176-199501000-00014. View

2.
Urbanska M, Szajewska H . The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence. Eur J Pediatr. 2014; 173(10):1327-37. PMC: 4165878. DOI: 10.1007/s00431-014-2328-0. View

3.
Roman E, Moreno Villares J, Dominguez Ortega F, Carmona Martinez A, Pico Sirvent L, Santana Sandoval L . Real-world study in infants fed with an infant formula with two human milk oligosaccharides. Nutr Hosp. 2020; 37(4):698-706. DOI: 10.20960/nh.03084. View

4.
Dryl R, Szajewska H . Probiotics for management of infantile colic: a systematic review of randomized controlled trials. Arch Med Sci. 2018; 14(5):1137-1143. PMC: 6111368. DOI: 10.5114/aoms.2017.66055. View

5.
Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R . Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics. 2010; 126(3):e526-33. DOI: 10.1542/peds.2010-0433. View